Brief: PharmAbcine Execute An Agreement With Thermo Fisher For Development, Manufacturing Of Its Next-Generation Immune Checkpoint Blockade
June 10 (Reuters) - PharmAbcine Inc 208340.KQ :
* PHARMABCINE EXECUTE AN AGREEMENT WITH THERMO FISHER FOR
THE
DEVELOPMENT AND MANUFACTURING OF ITS NEXT-GENERATION IMMUNE
CHECKPOINT BLOCKADE, PMC-309 FOR PHASE I
Source text for Eikon: ID:nPn7TlHyma
Further company coverage: 208340.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration